Press Release

Plymouth, MI [April 8, 2012] – Esperion Therapeutics, Inc. today announced the appointment of Noah Rosenberg, MD, as its chief medical officer (CMO).  Dr. Rosenberg will lead the Esperion clinical advisory board and will develop and manage the company’s clinical programs.  He will also manage the regulatory review process for the company’s innovative investigational therapies to prevent, treat and reverse cardiovascular and metabolic diseases.  In addition, Dr. Rosenberg will play an instrumental role in corporate planning related to financing to support the ongoing development of the company’s novel portfolio.

“Dr. Rosenberg is a terrific addition to the Esperion team,” commented Esperion’s president and CEO, Roger Newton, adding, “After an extensive nationwide search, Noah’s broad industry-specific experience and his passion for translating basic research to therapeutic applications impressed me most.  He has a proven track record of establishing, building and leading teams in cardiometabolic disease with a focus on results-driven drug development.”

Over the past decade, Dr. Rosenberg has held senior posts in the pharmaceutical industry, including leadership roles in medical affairs, clinical development and administration in the US and globally at Pfizer, sanofi-aventis and Forest Labs. He has experience working on compounds in all phases of drug development including late stage drugs such as Lipitor and Lantus. Most recently at Forest Research Institute (FRI), , he led the successful in-licensing of the GK1-399 program and, until his departure, served as a standing member of the Joint Development Committee (JDC) with partner TransTech Pharma.  Noah also coordinated the successful integration of the Forest cardiovascular and metabolism clinical development teams and managed the group through a highly productive period, helping to strengthen a pipeline that ultimately included compounds such as bystolic and azimilide.  Dr. Rosenberg was trained in internal medicine at The Mount Sinai Hospital/Mount Sinai School of Medicine in New York City, where he also served as a faculty member in internal medicine and emergency medicine.  He earned a MD from Drexel University and a BA in natural sciences from The Johns Hopkins University.

"I am excited at the prospect of working with such an innovative research team.  Esperion has an established reputation for productivity and success and I look forward to moving novel therapies such as ETC-1002 further along in clinical development,” Dr. Rosenberg said.

About Esperion Therapeutics
Esperion Therapeutics, Inc. discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company intends to commercialize innovative, first-in-class therapies focused on promoting cardio-metabolic health. For more information please visit www.esperion.com.